femtogenix.comAbout company
Femtogenix was founded in 2015 to discover and develop next generation DNA-interactive payload molecules for use in antibody-drug conjugates. their payloads are designed through a development platform combining proprietary computational chemistry techniques, and founder know-how gained from a combined 50+ years of experience in DNA-targeted drug discovery and development. Their drug discovery platform allows us to design molecules capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumour cells. When attached to antibodies or other targeting moieties, these potent cytototoxic agents can be delivered directly to tumours with minimal general systemic toxicities for patients.
